SC restrains Glenmark from selling copy of Merck’s diabetes drug

By: Indu Bhan

The Supreme Court on Friday restrained Glenmark Pharmaceuticals from the manufacture and institutional sales of branded generic versions of anti-diabetes drug, Sitagliptin, till July 22 even as it allowed it to continue selling existing stocks, asking the trial judge to decide expeditiously on the company’s dispute with US-based Merck, which holds a patent on the drug.

[related-post]

Subscriber Only Stories

View All

UPSC Key- January 30, 2023: Know about Project 39A, Beating Retreat Cerem...

UPSC Essentials | Key terms of the past week with MCQs

ExplainSpeaking: How to evaluate a Union Budget

Mahesh Vyas writes: Why the job shortage is for real

Apply New Year promo code SD25

Meanwhile, drug major Sun Pharmaceutical said it is reviewing a complaint by Meijer Inc alleging anti-trust in connection with Ranbaxy securing market exclusivity for certain products. “Meijer filed complaint, alleging antitrust and RICO Act violations in connection with Ranbaxy securing market exclusivity as part of the FDA’s approval for certain products,” Sun Pharmaceutical said.

With inputs from PTI